Reuters: Regulatory News: FDA review backs Cornerstone drug for low salt

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

FDA review backs Cornerstone drug for low salt Sep 11th 2012, 12:38 WASHINGTON, Sept 11 | Tue Sep 11, 2012 8:38am EDT WASHINGTON, Sept 11 (Reuters) - A clinical reviewer from the U.S. Food and Drug Administration on Tuesday recommended the agency approve Cornerstone Therapeutics Inc's drug to treat low sodium levels in one condition. Dr. Nancy Xu, a clinical reviewer at the FDA, said the drug lixivaptan should be approved to treat low sodium levels due to a condition that causes the body to have excess water. However, she said the drug should not be approved for heart failure patients, which the company had also sought. The FDA staff review comes ahead of an advisory panel of outside experts, which will vote on whether to recommend the drug on Thursday. The FDA will make a final decision later, taking into account the panel's recommendations.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions